FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ariel Gordin

Research Profile

Chemicals & Drugs

Disorders

Procedures

Physiology

Hemodynamics

Concepts & Ideas

Reference Values

Co-author Network

Publications

TOP 3
Outi Paija; Kari Laine; Eeva-Riitta Kultalahti; Mika Leinonen; Risto Huupponen; Ariel Gordin; Kari Reinikainen
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
Ariel Gordin; Seppo Kaakkola; Heikki Teräväinen
Clinical advantages of COMT inhibition with entacapone - a review.
Jan Petter Larsen; J Worm-Petersen; A Sidén; Ariel Gordin; Kari Reinikainen; Mika Leinonen
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ariel Gordin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2005: Outi Paija; Kari Laine; Eeva-Riitta Kultalahti; Mika Leinonen; Risto Huupponen; Ariel Gordin; Kari Reinikainen
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
Clinical neuropharmacology 2005;28(3):115-9.
2004: Ariel Gordin; Seppo Kaakkola; Heikki Teräväinen
Clinical advantages of COMT inhibition with entacapone - a review.
Journal of neural transmission (Vienna, Austria : 1996) 2004;111(10-11):1343-63.
2003: Jan Petter Larsen; J Worm-Petersen; A Sidén; Ariel Gordin; Kari Reinikainen; Mika Leinonen
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2003;10(2):137-46.
2003: Ariel Gordin; Seppo Kaakkola; Heikki Teräväinen
Position of COMT inhibition in the treatment of Parkinson's disease.
Advances in neurology 2003;91():237-50.
2002: Jukka Lyytinen; Seppo Kaakkola; Ariel Gordin; Eeva-Riitta Kultalahti; Heikki Teräväinen; Anssi Sovijärvi
The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.
Parkinsonism & related disorders 2002;8(5):349-55.
2002: Werner Poewe; Günther Deuschl; Ariel Gordin; Eeva-Riitta Kultalahti; Mika Leinonen
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Acta neurologica Scandinavica 2002;105(4):245-55.
2001: Heikki Teräväinen; UK Rinne; Ariel Gordin
Catechol-O-methyltransferase inhibitors in Parkinson's disease.
Advances in neurology 2001;86():311-25.
2001: Jukka Lyytinen; Anssi Sovijärvi; Seppo Kaakkola; Ariel Gordin; Heikki Teräväinen
The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
Clinical neuropharmacology 2001;24(1):50-7.
2000: Paola Piccini; David J Brooks; K Korpela; Nicola Pavese; M Karlsson; Ariel Gordin
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 2000;68(5):589-94.
1999: Juha Rouru; Ariel Gordin; Risto Huupponen; Sakke Huhtala; Eriika Savontaus; K Korpela; Kari Reinikainen; Mika Scheinin
Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
European journal of clinical pharmacology 1999;55(6):461-7.
1999: UK Rinne; Ariel Gordin; Heikki Teräväinen
COMT inhibition with entacapone in the treatment of Parkinson's disease.
Advances in neurology 1999;80():491-4.
1998: Iñaki F Trocóniz; T H Naukkarinen; HM Ruottinen; UK Rinne; Ariel Gordin; M O Karlsson
Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.
Clinical pharmacology and therapeutics 1998;64(1):106-16.
1996: A Illi; S Sundberg; P Ojala-Karlsson; Mika Scheinin; Ariel Gordin
Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
Clinical pharmacology and therapeutics 1996;59(4):450-7.
1996: A Illi; S Sundberg; P Ojala-Karlsson; Mika Scheinin; Ariel Gordin
Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions.
European journal of clinical pharmacology 1996;51(3-4):273-6.
1996: T Keränen; Ariel Gordin; Markku Koulu; Mika Scheinin; Saila Antila; S Sundberg; T Wikberg
COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.
Journal of neural transmission (Vienna, Austria : 1996) 1996;103(6):729-36.
1995: A Illi; S Sundberg; P Ojala-Karlsson; P Korhonen; Mika Scheinin; Ariel Gordin
The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine.
Clinical pharmacology and therapeutics 1995;58(2):221-7.
1995: S Ahtila; Seppo Kaakkola; Ariel Gordin; K Korpela; S Heinävaara; M Karlsson; T Wikberg; P Tuomainen; Pekka T Männistö
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.
Clinical neuropharmacology 1995;18(1):46-57.
1994: A Illi; S Sundberg; Markku Koulu; Mika Scheinin; S Heinävaara; Ariel Gordin
COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise.
International journal of clinical pharmacology and therapeutics 1994;32(11):582-8.
1994: Seppo Kaakkola; Ariel Gordin; Pekka T Männistö
General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
General pharmacology 1994;25(5):813-24.
1994: Seppo Kaakkola; Heikki Teräväinen; S Ahtila; Hannu Rita; Ariel Gordin
Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients.
Neurology 1994;44(1):77-80.
1994: T Keränen; Ariel Gordin; M Karlsson; K Korpela; P J Pentikäinen; Hannu Rita; E Schultz; L Seppälä; T Wikberg
Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.
European journal of clinical pharmacology 1994;46(2):151-7.
1993: S Sundberg; Mika Scheinin; A Illi; Juha Akkila; Ariel Gordin; T Keränen
The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise.
British journal of clinical pharmacology 1993;36(5):451-6.
1993: T Keränen; Ariel Gordin; V P Harjola; M Karlsson; K Korpela; P J Pentikäinen; Hannu Rita; L Seppälä; T Wikberg
The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
Clinical neuropharmacology 1993;16(2):145-56.
1993: S Sundberg; Mika Scheinin; P Ojala-Karlsson; Juha Akkila; Ariel Gordin
The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition.
European journal of clinical pharmacology 1993;44(3):287-90.
1991: S Sundberg; Ariel Gordin
COMT inhibition with nitecapone does not affect the tyramine pressor response.
British journal of clinical pharmacology 1991;32(1):130-2.
1991: Raimo K Tuominen; R Lehtinen; Juha Peltola; R Wikberg; Ariel Gordin; P Kokkonen; P Pohto
Penetration of erythromycin into periapical lesions after repeated doses of erythromycin acistrate and erythromycin stearate: a pilot study.
Oral surgery, oral medicine, and oral pathology 1991;71(6):684-8.
1991: S Sundberg; O J Luurila; A Kohvakka; Ariel Gordin
The circadian heart rate but not blood pressure profile is influenced by the timing of beta-blocker administration in hypertensives.
European journal of clinical pharmacology 1991;40(4):435-6.
1991: E Schultz; S Tarpila; A C Bäckström; Ariel Gordin; E Nissinen; P Pohto
Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone.
European journal of clinical pharmacology 1991;40(6):577-80.
1990: Seppo Kaakkola; Ariel Gordin; M Järvinen; T Wikberg; E Schultz; E Nissinen; P J Pentikäinen; Hannu Rita
Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
Clinical neuropharmacology 1990;13(5):436-47.
1990: S Sundberg; Mika Scheinin; P Ojala-Karlsson; S Kaakkola; Juha Akkila; Ariel Gordin
Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone.
Clinical pharmacology and therapeutics 1990;48(4):356-64.
1990: Sanna Siitonen; Heikki Vapaatalo; S Salminen; Ariel Gordin; Maija Saxelin; R Wikberg; Anna-Leena Kirkkola
Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea.
Annals of medicine 1990;22(1):57-9.
1990: Juhani Lehtola; P Jauhonen; A Kesäniemi; R Wikberg; Ariel Gordin
Effect of erythromycin on the oro-caecal transit time in man.
European journal of clinical pharmacology 1990;39(6):555-8.
1989: S S Kaukoranta-Tolvanen; O V Renkonen; Ariel Gordin; L Tamm; Pekka T Männistö
Effect of erythromycin acistrate and erythromycin stearate on human colonic microflora.
Scandinavian journal of infectious diseases 1989;21(6):717-20.
1988: Ariel Gordin; Pekka T Männistö; R Antikainen; S Savolainen; J Ylikoski; P Kokkonen; V Rauramaa
Concentrations of erythromycin, 2'-acetyl erythromycin, and their anhydro forms in plasma and tonsillar tissue after repeated dosage of erythromycin stearate and erythromycin acistrate.
Antimicrobial agents and chemotherapy 1988;32(7):1019-24.
1988: Ariel Gordin; H A Salmi; R Antikainen
Erythromycin acistrate and enterocoated pellets of erythromycin base in acute respiratory infections of hospitalized conscripts.
The Journal of antimicrobial chemotherapy 1988;21 Suppl D():93-9.
1988: Ariel Gordin; S Kalima; S Hulmi; P Mäkelä; R Antikainen
Comparison of erythromycin acistrate and enterocoated erythromycin base in acute respiratory infections.
The Journal of antimicrobial chemotherapy 1988;21 Suppl D():85-92.
1988: S Savolainen; Pekka T Männistö; Ariel Gordin; R Antikainen; H Haataja; Raimo K Tuominen; J Ylikoski
Tonsillar penetration of erythromycin and its 2'-acetyl ester in patients with chronic tonsillitis.
The Journal of antimicrobial chemotherapy 1988;21 Suppl D():73-84.
1988: T Rostila; K Visa; Ariel Gordin; R Antikainen
Erythromycin acistrate and erythromycin stearate in the treatment of non-gonococcal urethritis.
The Journal of antimicrobial chemotherapy 1988;21 Suppl D():113-9.
1988: O P Salo; Ariel Gordin; H Brandt; R Antikainen
Efficacy and tolerability of erythromycin acistrate and erythromycin stearate in acute skin infections of patients with atopic eczema.
The Journal of antimicrobial chemotherapy 1988;21 Suppl D():101-6.
1988: S Sundberg; A Kohvakka; Ariel Gordin
Rapid reversal of circadian blood pressure rhythm in shift workers.
Journal of hypertension 1988;6(5):393-6.
1987: Ariel Gordin; S Kalima; P Mäkelä; R Antikainen
Comparison of three- and ten-day regimens with a sulfadiazine-trimethoprim combination and pivmecillinam in acute lower urinary tract infections.
Scandinavian journal of infectious diseases 1987;19(1):97-102.
1987: S Sundberg; K Tiihonen; Ariel Gordin
Vasodilatory effects of carvedilol and pindolol.
Journal of cardiovascular pharmacology 1987;10 Suppl 11():S76-80.
1986: Ariel Gordin; P Pohto; S Sundberg; S Nykänen; H Haataja; P Männistö
Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers.
European journal of clinical pharmacology 1986;31(4):423-6.